Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

PURPOSE Since febrile neutropenic patients were recognized to constitute a heterogeneous population, several models have been developed for predicting the risk of serious medical complications. The Multinational Association for Supportive Care in Cancer score and its derived clinical prediction rules have been validated, but thus far there were no data about its use for simplifying therapy in predicted low-risk patients. PATIENTS AND METHODS In a single institution, we followed all episodes of febrile neutropenia between January 1999 and November 2003. Those patients predicted at low risk for complications, who were not receiving antibacterials at fever onset and were eligible for treatment with oral antibiotics, were treated with ciprofloxacin and amoxicillin-clavulanate and were discharged if they were clinically stable or improving after an initial observation period. The primary end point of the study was the rate of resolution of the febrile neutropenic episode without complications, among these early discharged patients. RESULTS Of 383 first febrile neutropenic episodes predicted at low risk of complication, 178 patients (33 men and 145 women, mainly with solid tumors) were treated orally; they constituted the basis of our analysis. Seventy-nine patients (44%) were discharged early (with a median time to discharge of 26 hours); no complications occurred among them but three patients had to be readmitted, resulting in a success rate of 96% (95% CI, 92% to 100%). CONCLUSION Our study shows that oral therapy followed by early discharge was feasible in a small but significant proportion of patients selected by a strategy combining predicted low risk and medical and nonmedical criteria.

[1]  L. Young,et al.  Erratum: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever (J. Infec. Dis. 1990; 161:381-396) , 1990 .

[2]  L. Young,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1997 .

[3]  W. Khan,et al.  Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. , 1995, The American journal of medicine.

[4]  R. Finberg,et al.  Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Finberg,et al.  Fever and neutropenia--how to use a new treatment strategy. , 1999, The New England journal of medicine.

[7]  R. Mayer,et al.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. , 1988, Archives of internal medicine.

[8]  L. Young,et al.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.

[9]  R. Benjamin,et al.  Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer , 1993, Cancer.

[10]  R. Finberg,et al.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Elting,et al.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. O'Ryan,et al.  Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Paesmans,et al.  Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1999, The New England journal of medicine.

[15]  P. Clark,et al.  Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study , 2003, British Journal of Cancer.

[16]  S. Steinberg,et al.  A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. , 1999, The New England journal of medicine.

[17]  B. Rapoport,et al.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score , 2004, Supportive Care in Cancer.

[18]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[19]  M. Paesmans,et al.  Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.